

Hyperbaric Oxygen Therapy

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Hyperbaric Oxygen Therapy	1
Summary	2
Definitions	2
Medical Necessity Criteria for Clinical Review	2
General Medical Necessity Criteria	2
Indication-Specific Criteria	3
Acute air or gas embolism	3
Acute carbon monoxide poisoning	3
Acute traumatic peripheral ischemia	3
Anemia	3
Burns	3
Central retinal artery (CRA) occlusion	4
Chronic diabetic ulcer	4
Compromised skin grafts or flaps	4
Crush injuries and compartment syndrome	4
Carbon monoxide poisoning	5
Idiopathic sudden sensorineural hearing loss	5
Intracranial abscess	5
Necrotizing soft tissue infections and gas gangrene (Clostridial myositis and myonecrosis)	5
Osteomyelitis	5

Radiation injury	6
Experimental, Investigational, or Unproven / Not Medically Necessary	6
Absolute Contraindications for Hyperbaric Oxygen	6
Experimental, Investigational, or Unproven	6
Topical Application of Oxygen	8
Applicable Billing Codes	8
References	17
Clinical Guideline Revision / History Information	21

Summary

The Plan considers systemic hyperbaric oxygen therapy (HBOT) medically necessary when the criteria below for certain medical conditions are met for a prior authorization review. According to the Undersea and Hyperbaric Medical Society (UHMS), hyperbaric oxygen therapy applies an increased pressure of ≥ 1 atmosphere absolute at sea level with $\geq 95\%$ oxygen to the body leading to augmented oxygen levels in the blood to accelerate improvement of conditions. Hyperbaric oxygen chambers have received FDA clearance for use in specific indications.. Most commonly, HBOT is used to treat chronic complex diabetic wounds of the lower limbs. The Plan does not consider the topical application of oxygen medically necessary under any circumstances.

Definitions

“Hyperbaric oxygen therapy” (HBOT) is a method in which the entire body is exposed to oxygen under increased atmospheric pressure.

“Continuous topical oxygen therapy” (CTOT) is a portable unit that can provide continuous flow of atmospheric (normobaric) oxygen to the wound up to 24 hours a day and 7 days a week. This does not require the member to be in-clinic and immobilized for therapy.

“Standard wound care” in patients with diabetic wounds includes the assessment of a patient’s vascular status and correction of any vascular problems in the affected limb if possible; optimization of nutritional status, optimization of glucose control; debridement by any means to remove devitalized tissue; maintenance of a clean, moist bed of granulation tissue with appropriate moist dressings; appropriate off-loading; and necessary treatment to resolve any infection that might be present.

Medical Necessity Criteria for Clinical Review

General Medical Necessity Criteria

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. HBOT must be prescribed and administered by the licensed treating physician; *and*
2. HBOT must be administered in a chamber (such as the single-patient unit or multiplace unit);
and

3. Continued HBOT is limited to 30-day authorization periods unless otherwise noted in the criteria below. Continued HBOT is subject to review for medical necessity and is indicated only when ALL of the following criteria are met:
 - a. Adherence to hyperbaric oxygen therapy; *and*
 - b. Evidence of improvement during the authorization period, e.g., reduction in the size of wound and reduction in signs of infection and/or inflammation.

Indication-Specific Criteria

The Plan considers HBOT medically necessary for the following conditions when the General Medical Necessity Criteria AND at least one of the Indication-Specific Criteria are met:

Acute air or gas embolism

The Plan considers HBOT medically necessary when ONE of the following criteria is met:

1. 1 treatment may be indicated; *or*
2. Additional treatments may be indicated only if symptoms persist.

Acute carbon monoxide poisoning

The Plan considers HBOT medically necessary when ONE of the following criteria is met:

1. 1 to 3 total treatments may be indicated depending on persistence of clinical symptoms.

Acute traumatic peripheral ischemia

The Plan considers HBOT medically necessary when ONE of the following criteria is met:

1. There is an immediate threat of permanent dysfunction, loss of limb, or death.

Anemia

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. Member unable or unwilling to receive a red blood cell transfusion; *and*
2. Emergent treatment, as indicated by 1 or more of the following:
 - a. Active hemolysis with progressive anemia; *or*
 - b. Acute blood loss or active massive hemorrhage; *or*
 - c. Hypovolemic shock.

Burns

The Plan considers HBOT medically necessary when ONE of the following criteria is met:

1. Large or severe burns that are treated at a specialized burn center.

Central retinal artery (CRA) occlusion

The Plan considers HBOT medically necessary when ONE of the following criteria is met:

1. When started within 24 hours of symptom onset - treatment is typically indicated until CRA recanalization has occurred (usually 24-72 hours).

Chronic diabetic ulcer

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. Severe wound (Wagner Grade III or higher) based on at least ONE of the following criteria:
 - a. Deep ulceration to tendon causing tendonitis or non-infected bone; *or*
 - b. Deep ulcer with infection (e.g., abscess, osteomyelitis, or joint sepsis); *or*
 - c. Localized gangrene (ischemia) of the forefoot or heel; *and*
2. Prior evaluation and treatment of underlying peripheral vascular and/or neuropathic disease; *and*
3. Documented 30-day trial of conventional wound care for diabetes with minimal to no healing and meets ALL of the following:
 - a. Glycemic optimization; *and*
 - b. Wound is not infected or has been treated with antibiotics; *and*
4. Treatment is indicated daily and meets ALL of the following:
 - a. Evaluation of the wound occurs at least every 30 days during HBOT and demonstrates measurable signs of healing; *and*
 - b. Treatment is ordered for no more than 40 HBOT treatments to allow for review of the evaluation.

Compromised skin grafts or flaps

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. Hypoxia or decreased perfusion has compromised viability acutely of skin grafts or flaps; *and*
2. Correctable causes of the flap failure have been explored and adequately addressed prior to initiation of HBOT; *and*
3. Treatment is indicated for 2 times per day until the graft or flap appears viable, then 1 time per day until healed; *and*
4. Efficacy of therapy should be reviewed after 20 treatments and discontinued if no clinical improvement.

Crush injuries and compartment syndrome

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. When there is immediate threat of permanent dysfunction, loss of limb, or death; *and*
2. Treatment is indicated for 7 days or 14 treatment sessions. Treatment typically should occur twice a day for two days, then daily for two days.

Carbon monoxide poisoning

The Plan considers HBOT medically necessary when ONE of the following criteria is met:

1. Carbon monoxide poisoning with or without Cyanide poisoning.

Decompression illness

The Plan considers HBOT medically necessary when ONE of the following criteria is met:

1. Treatment should be rapid and repeated up to 10 times only if symptoms persist.

Idiopathic sudden sensorineural hearing loss

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. Audiometry showing a 30-dB hearing loss at 3 consecutive frequencies; *and*
2. Other underlying potential causes have been ruled out or are not applicable; *and*
3. HBOT is given in conjunction with standard of care steroid therapy; *and*
4. 15 to 20 total treatments may be indicated once daily only when HBOT is initiated within 3 months after onset.

Intracranial abscess

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. Member has multiple abscesses, abscesses in a deep or dominant location, or is immunocompromised; *and*
2. ONE of the following criteria:
 - a. Member has not responded to or is deteriorating despite standard of care, surgical and/or antibiotic treatment; *or*
 - b. Member is not a candidate for surgery due to high risks or contraindications; *and*
3. Treatment may be indicated for 1-2 times per day; *and*
4. Efficacy of therapy should be reviewed after 20 treatments and discontinued if no clinical improvement.

Necrotizing soft tissue infections and gas gangrene (Clostridial myositis and myonecrosis)

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. Documentation from a treating physician stating HBOT is used in conjunction with surgical debridement and antibiotics; *and*
2. Treatment is ordered and indicated for 2 times per day until there is no further extension of necrosis in previously debrided areas; *and*
3. Efficacy of therapy should be reviewed after 30 treatments and discontinued if no clinical improvement.

Osteomyelitis

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. The diagnosis is confirmed by imaging or biopsy; *and*
2. Documentation from a treating physician confirms that the member is unresponsive to conventional medical and surgical management; *and*
3. Member has completed at least 6 weeks of appropriate IV antibiotic therapy; *and*
4. Member has undergone surgery without resolution or has documented justification for why surgery is not an option.

Radiation injury

The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. The request is up to 40 HBOT treatments; *and*
2. ONE of the following criteria is met:
 - a. Osteoradionecrosis (e.g., radiation-induced osteonecrosis of the jaw) as an adjunct to conventional treatment; *or*
 - b. Soft tissue radionecrosis as an adjunct to conventional treatment; *or*
 - c. Radiation-induced hemorrhagic cystitis; *or*
 - d. Radiation-induced proctitis; *or*
 - e. Prophylactic prevention of osteonecrosis of the jaw following tooth extraction in an irradiated field with ONE of the following:
 - i. Prior to surgery, treatment is ordered and indicated for 20 HBOT treatments; *or*
 - ii. Immediately after surgery, treatment is ordered and indicated for 10 HBOT treatments.

Experimental, Investigational, or Unproven / Not Medically Necessary

Absolute Contraindications for Hyperbaric Oxygen

1. Concurrent administration of the antibiotic cream mafenide (Sulfamylon)
2. Concurrent administration of disulfiram (Antabuse)
3. Concurrent administration of antineoplastic agent doxorubicin
4. Concurrent or past administration of antineoplastic agents bleomycin or cisplatin (Platinol)
5. Premature infants (birth prior to 37 weeks gestation)
6. Untreated pneumothorax

Experimental, Investigational, or Unproven

The Plan considers the use of HBOT to be experimental, investigational, or unproven in the treatment of the following conditions including but not limited to:

1. Actinomycosis
2. Acute cerebral edema
3. Acute coronary syndrome

4. Acute or chronic cerebrovascular insufficiency
5. Acute thermal and chemical pulmonary damage (i.e., smoke inhalation with pulmonary insufficiency)
6. Aerobic infection
7. AIDS/HIV
8. Alzheimer's disease
9. Anaerobic infection other than Clostridial
10. Anoxic brain injury
11. Arthritic diseases
12. Asthma
13. Autism
14. Bell's palsy
15. Cancer
16. Cardiogenic shock
17. Cerebral palsy
18. Chronic fatigue syndrome
19. Chronic peripheral vascular insufficiency
20. Coronary artery disease
21. COVID-19 or Long COVID
22. Cutaneous, decubitus, and venous stasis ulcers
23. Depression
24. Fibromyalgia
25. Fractures or fracture non-union
26. Heart disease
27. Hepatic necrosis
28. Hepatitis
29. Inflammatory bowel disease
30. Ischemic stroke
31. Lyme disease
32. Malignant otitis externa
33. Meningioma
34. Migraine and cluster headaches
35. Multiple sclerosis
36. Myocardial infarction
37. Non-compromised skin grafts and flaps
38. Osteonecrosis of the jaw (not induced by radiation)
39. Osteoporosis
40. Parkinson's disease
41. Post-concussive syndrome
42. Pulmonary emphysema
43. Following Radiation injuries:

- a. Radiation-induced retinitis pigmentosa
 - b. Radiation-induced retinopathy
 - c. Radiation-induced neurologic injury
 - d. Radiation-induced xerostomia
 - e. Radiation-induced soft tissue injury (unless the above criteria is met)
- 44. Senility
 - 45. Sick cell anemia
 - 46. Spinal cord injury
 - 47. Stroke
 - 48. Surgical wound dehiscence
 - 49. Tetanus
 - 50. Tinnitus
 - 51. Traumatic brain injury
 - 52. Vascular dementia

Topical Application of Oxygen

This method of oxygen administration does not meet the definition of HBOT as stated above and there are no high-quality, evidence-based studies supporting its use in the literature. In 2022, Hayes rated topical oxygen therapy for chronic wound healing as D2. According to Hayes, clinical evidence suggests that it is associated with a reduction in wound size and pain; however, only 1 study evaluated complete wound closure. The comparative effectiveness is unclear due to the poor quality and lack of studies evaluating HBOT with a competing alternative. No guidance currently recommends use of topical HBOT. (UHMS, 2018). A recent small, randomized control trial (Yu et al. 2016) claimed a significant difference in healing rates between patients receiving topical oxygen therapy and those receiving standard wound care. However, the study was underpowered; it is unclear how many patients were included in each of the ulcer "stage" groups and statistical analysis is lacking. In addition, a small case series of 3 patients (Agarwal et al. 2015) described a device for applying topical oxygen and stated that these patients required fewer debridements, but there was no control group. A larger, multi-center study (Dryden et al. 2016) evaluated topical oxygen gel for both acute and chronic wounds with delayed healing, but again was simply observational and did not compare outcomes to any control group. While these study results may be promising in regard to topical oxygen therapy (TOT), as a treatment modality for including but not limited to chronic non-healing wounds, additional randomized comparative controlled studies are required to assess the effectiveness of this therapy. Currently, there are no society guidelines that provide recommendations regarding the use of TOT. The current evidence is insufficient in determining the effects of this technology on net health outcomes and supports the categorization of topical oxygen therapy as experimental and investigational. Experimental and investigational treatments are not covered by the Plan. Topical HBOT includes boot or bag systems and single limb or sacral chambers.

Applicable Billing Codes

Table 1	
CPT/HCPCS codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
99183	Physician attendance and supervision of hyperbaric oxygen therapy, per session
G0277	Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval

Table 2	
ICD-10 codes considered experimental, investigational, or unproven:	
<i>Code</i>	<i>Description</i>
A00.0 - A00.9	Cholera
A01.00 - A01.4	Typhoid and paratyphoid fevers
A02.0 - A02.9	Other salmonella infections
A03.0 – A03.9	Shigellosis
A04.0	Enteropathogenic Escherichia coli infection
A04.1	Enterotoxigenic Escherichia coli infection
A04.2	Enteroinvasive Escherichia coli infection
A04.3	Enterohemorrhagic Escherichia coli infection
A04.4	Other intestinal Escherichia coli infections
A04.5	Campylobacter enteritis
A04.6	Enteritis due to Yersinia enterocolitica
A04.8	Other specified bacterial intestinal infections
A04.9	Bacterial intestinal infection, unspecified

Table 2	
ICD-10 codes considered experimental, investigational, or unproven:	
<i>Code</i>	<i>Description</i>
A05.0	Foodborne staphylococcal intoxication
A05.1	Botulism food poisoning
A05.3	Foodborne <i>Vibrio parahaemolyticus</i> intoxication
A05.4	Foodborne <i>Bacillus cereus</i> intoxication
A05.5	Foodborne <i>Vibrio vulnificus</i> intoxication
A05.8	Other specified bacterial foodborne intoxications
A05.9	Bacterial foodborne intoxication, unspecified
A06.0 - A06.9	Amebiasis
A07.0 - A07.9	Other protozoal intestinal diseases
A08.0 - A08.9	Viral and other specified intestinal infections
A09	Infectious gastroenteritis and colitis, unspecified
A15.0 - A19.9	Tuberculosis
A20.0 - A28.9	Certain zoonotic bacterial diseases
A30.0 - A46, A48.1 - A49.9	Other bacterial diseases
A50.01 - A64	Infections with a predominantly sexual mode of transmission
A65 - A69.9	Other spirochetal diseases
A70 - A74.9	Other diseases caused by chlamydiae
A75.0 - A79.9	Rickettsioses
A80.0 - A89	Viral and prion infections of the central nervous system
A90 - A99	Arthropod-borne viral fevers and viral hemorrhagic fevers
B00.0 - B09	Viral infections characterized by skin and mucous membrane lesions

Table 2	
ICD-10 codes considered experimental, investigational, or unproven:	
<i>Code</i>	<i>Description</i>
B10.0 - B10.89	Other human herpesviruses
B15.0 - B19.9	Viral hepatitis
B20	Human immunodeficiency virus [HIV] disease
B25.0 - B34.9	Other viral diseases
B35.0 - B49	Mycoses
B50.0 - B64	Protozoal diseases
B65.0 - B83.9	Helminthiasis
B85.0 - B89	Pediculosis, acariasis and other infestations
B90.0 - B94.9	Sequelae of infectious and parasitic diseases
B95.0 - B95.8	Streptococcus, Staphylococcus, and Enterococcus as the cause of diseases classified elsewhere
B96.1	Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified elsewhere
B96.20 - B96.29	Escherichia coli [E. coli] as the cause of diseases classified elsewhere
B96.3	Hemophilus influenzae [H. influenzae] as the cause of diseases classified elsewhere
B96.4	Proteus (mirabilis) (morganii) as the cause of diseases classified elsewhere
B96.5	Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere
B96.6	Bacteroides fragilis [B. fragilis] as the cause of diseases classified elsewhere
B96.81 - B96.89	Other specified bacterial agents as the cause of diseases classified elsewhere
B97.0 - B97.89	Viral agents as the cause of diseases classified elsewhere
B99.8 - B99.9	Other infectious diseases

Table 2	
ICD-10 codes considered experimental, investigational, or unproven:	
<i>Code</i>	<i>Description</i>
C00.0 - C96.9	Malignant neoplasms
D00.00 - D09.9	In situ neoplasms
D32.0 - D32.9	Benign neoplasm of meninges
D42.0 - D42.9	Neoplasm of uncertain behavior of meninges
D57.00 - D57.819	Sickle-cell disorders
F01.50 - F01.C4	Vascular dementia
F07.81	Postconcussional syndrome
F32.0 - F32.A	Depressive episode
F33.0 - F33.9	Major depressive disorder, recurrent
F84.0	Autistic disorder
G20.A1 - G20.C	Parkinson's disease
G30.0 - G30.9	Alzheimer's disease
G35	Multiple sclerosis
G43.001 - G43.E19	Migraine
G44.001 - G44.009	Cluster headache syndrome, unspecified
G44.011 - G44.019	Episodic cluster headache
G44.021 - G44.029	Chronic cluster headache
G51.0	Bell's palsy
G62.82	Radiation-induced polyneuropathy

Table 2	
ICD-10 codes considered experimental, investigational, or unproven:	
<i>Code</i>	<i>Description</i>
G80.0 - G80.9	Cerebral palsy
G93.1	Anoxic brain damage, not elsewhere classified
G93.32	Myalgic encephalomyelitis/chronic fatigue syndrome
G93.6	Cerebral edema
G98.0	Neurogenic arthritis, not elsewhere classified
H31.021 - H31.029	Solar retinopathy
H60.20 - H60.23	Malignant Otitis Externa
H93.11 - H93.19	Tinnitus
I05.0 - I09.9	Chronic rheumatic heart diseases
I20.0 - I25.9	Ischemic heart diseases
I27.0 - I27.9	Other pulmonary heart diseases
I30.0 - I5A	Other forms of heart disease
I63.0 - I63.9	Cerebral infarction
I65.01 - I65.9	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction
I66.01 - I66.9	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction
I67.0 - I67.9	Other cerebrovascular diseases
I83.001 - I83.229	Varicose veins of lower extremities with ulcer
I87.2	Venous insufficiency (chronic) (peripheral)
I87.311 - I87.319	Chronic venous hypertension (idiopathic) with ulcer
I87.331 - I87.339	Chronic venous hypertension (idiopathic) with ulcer and inflammation
J43.0 - J43.9	Emphysema

Table 2	
ICD-10 codes considered experimental, investigational, or unproven:	
<i>Code</i>	<i>Description</i>
J44.0 - J44.89	Other chronic obstructive pulmonary disease [bronchitis with emphysema]
J44.9	Chronic obstructive pulmonary disease, unspecified
J45.20 - J45.998	Asthma
J68.0 - J68.9	Respiratory conditions due to inhalation of chemicals, gasses, fumes and vapors
J70.0 - J70.9	Respiratory conditions due to other external agents
K50.00 - K50.919	Crohn's disease [regional enteritis]
K52.0	Gastroenteritis and colitis due to radiation
K52.89	Other specified noninfective gastroenteritis and colitis
K71.10	Toxic liver disease with hepatic necrosis, without coma
K71.11	Toxic liver disease with hepatic necrosis, with coma
K72.00	Acute and subacute hepatic failure without coma
K72.01	Acute and subacute hepatic failure with coma
K76.2	Central hemorrhagic necrosis of liver
L40.52	Psoriatic arthritis mutilans
L55.0 - L59.0	Radiation - related disorders of the skin and subcutaneous tissue
L89.000 - L89.96	Pressure ulcer
M00.00 - M25.9	Arthropathies
M48.40xA - M48.48xS	Fatigue fracture of vertebra
M79.7	Fibromyalgia

Table 2	
ICD-10 codes considered experimental, investigational, or unproven:	
<i>Code</i>	<i>Description</i>
M80.00xA - M80.0B9S	Osteoporosis with current pathological fracture
M80.80xA - M80.8B9S	Other osteoporosis with current pathological fracture
M81.0 - M81.8	Osteoporosis without current pathological fracture
M84.30XA - M84.38XS	Stress fracture
M87.180	Osteonecrosis due to drugs, jaw
M96.621- M96.69	Fracture of bone following insertion of orthopedic implant, joint prosthesis, or bone plate
M97.01XA - M97.9XXS	Periprosthetic fracture around internal prosthetic joint
P07.20 - P07.26	Extreme immaturity of newborn
P07.30 - P07.39	Preterm [premature] newborn [other]
P13.0	Fracture of skull due to birth injury
P13.4	Fracture of clavicle due to birth injury
R41.81	Age-related cognitive decline [senility]
R57.0	Cardiogenic shock
S06.0X0A - S06.9X9S	Intracranial injury
S12.000A - S12.9XXS	Fracture of cervical vertebra and other parts of neck
S14.0XXA - S14.2XXS	Injury of nerves and spinal cord at neck level
S22.000A - S22.9XXS	Fracture of rib(s), sternum and thoracic spine

Table 2	
ICD-10 codes considered experimental, investigational, or unproven:	
<i>Code</i>	<i>Description</i>
S24.0XXA - S24.2XXS	Injury of nerves and spinal cord at thorax level
S32.000A - S32.9XXS	Fracture of lumbar spine and pelvis
S34.01XA - S34.3XXS	Injury of lumbar and sacral spinal cord and nerves at abdomen, lower back and pelvis level
S42.001A - S42.92XS	Fracture of shoulder and upper arm
S52.001A - S52.92XS	Fracture of forearm
S62.001A - S62.92XS	Fracture at wrist and hand level
S72.001A - S72.92XS	Fracture of femur
S82.001A - S82.92xS	Fracture of lower leg, including ankle
S92.001A - S92.919S	Fracture of foot and toe, except ankle
T81.31XA - T81.31XS	Disruption of external operation (surgical) wound, not elsewhere classified
T81.320A - T81.329S	Disruption of internal operation (surgical) wound, not elsewhere classified
U07.1	COVID-19
U09.9	Post COVID-19 condition, unspecified
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status
Z86.16	Personal history of COVID-19

Table 3	
CPT/HCPCS codes considered experimental, investigational, or unproven:	
<i>Code</i>	<i>Description</i>
A4575	Topical hyperbaric oxygen chamber, disposable
E0446	Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories

References

1. Agarwal V, Aroor S, Gupta N, Gupta A, Agarwal N, Kaur N. New Technique of Applying Topical Oxygen Therapy as a Cost-Effective Procedure. *Indian J Surg*. 2015 Dec;77(Suppl 3):1456-9.
2. Agrawal, S. and N. Sharma, Complete recovery following hyperbaric oxygen therapy in idiopathic sudden sensorineural hearing loss--a report of two cases. *Undersea Hyperb Med*, 2016. 43(2): p. 161-6.
3. Armstrong, D.G. & J de Asla, R. (Jan 2021). *Management of diabetic foot ulcers*. UpToDate.com. <https://www.uptodate.com/contents/management-of-diabetic-foot-ulcers>
4. Arslan A. (2021). Hyperbaric oxygen therapy in carbon monoxide poisoning in pregnancy: Maternal and fetal outcome. *The American Journal of Emergency Medicine*. 43, 41-45.
5. Aydin, F. (2023). Hyperbaric oxygen treatment in children: Experience in 329 patients. *Diving and Hyperbaric Medicine*, 53(3), 203–209. <https://doi.org/10.28920/dhm53.3.203-209>
6. Benedict Mitnick, C. D., & Johnson-Arbor, K. (2019). Atypical wounds: Hyperbaric oxygen therapy. *Clinics in Podiatric Medicine and Surgery*, 36(3), 525–533. <https://doi.org/10.1016/j.cpm.2019.02.008>
7. Bennett, M.H., et al., Hyperbaric oxygen therapy for late radiation tissue injury. *Cochrane Database of Systematic Reviews*, 2016(4).
8. Bennett, M.H., et al., Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache. *Cochrane Database of Systematic Reviews*, 2015(12).
9. Bennett, M.H., J.P. Lehm, and N. Jepson, Hyperbaric oxygen therapy for acute coronary syndrome. *Cochrane Database of Systematic Reviews*, 2015(7).
10. Bishop, A. J. (2015). Diabetic lower extremity ulcers and hyperbaric oxygen therapy. *J Endocrinol Diab*, 2(4), 1-5.
11. Borab, Z., Mirmanesh, M. D., Gantz, M., Cusano, A., & Pu, L. L. (2017). Systematic review of hyperbaric oxygen therapy for the treatment of radiation-induced skin necrosis. *Journal of Plastic, Reconstructive & Aesthetic Surgery*, 70(4), 529-538
12. Cardinal, J., Slade, A., McFarland, M., Keihani, S., Hotaling, J. N., & Myers, J. B. (2018). Scoping review and meta-analysis of hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. *Current urology reports*, 19, 1-8.

13. Casillas S, Galindo A, Camarillo-Reyes L A, et al. (October 15, 2019) Effectiveness of Hyperbaric Oxygenation Versus Normobaric Oxygenation Therapy in Carbon Monoxide Poisoning: A Systematic Review. *Cureus* 11(10): e5916. DOI 10.7759/cureus.5916
14. Celebi ARC. (2021). Hyperbaric Oxygen Therapy for Central Retinal Artery Occlusion: Patient Selection and Perspectives. *Clinical Ophthalmology*, 15, 3443-3457.
15. Clarke R. Monoplace chamber treatment of decompression illness: Review and commentary. *Diving Hyperb Med*. 2020 Sep 30;50(3):264-272. doi: 10.28920/dhm50.3.264-272. PMID: 32957129; PMCID: PMC7755460.
16. ClinicalTrials.gov. Hyperbaric Oxygen Therapy Effect on Post Concussion Syndrome in Children (TBIPED). NCT03339037. Retrieved from: <https://clinicaltrials.gov/ct2/show/NCT03339037>
17. Daly, S., Thorpe, M., Rockswold, S., Hubbard, M., Bergman, T., Samadani, U., & Rockswold, G. (2018). Hyperbaric oxygen therapy in the treatment of acute severe traumatic brain injury: a systematic review. *Journal of neurotrauma*, 35(4), 623-629.
18. Dryden M, Dickinson A, Brooks J, Hudgell L, Saeed K, Cutting KF. A multi-centre clinical evaluation of reactive oxygen topical wound gel in 114 wounds. *J Wound Care*. 2016 Mar;25(3):140-46.
19. Elraiyah, T., et al., A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers. *Journal of Vascular Surgery*, 2016. 63(2, Supplement): p. 46S-58S.e2.
20. Erdoğan, A., Düzgün, A. P., Erdoğan, K., Özkan, M. B., & Coşkun, F. (2018). Efficacy of hyperbaric oxygen therapy in diabetic foot ulcers based on Wagner classification. *The journal of foot and ankle surgery*, 57(6), 1115-1119.
21. Fernández, E., Morillo, V., Salvador, M., Santafé, A., Beato, I., Rodríguez, M., & Ferrer, C. (2021). Hyperbaric oxygen and radiation therapy: a review. *Clinical and Translational Oncology*, 23(6), 1047-1053.
22. Fife CE, Eckert KA, Carter MJ. An Update on the Appropriate Role for Hyperbaric Oxygen: Indications and Evidence. *Plast Reconstr Surg*. 2016 Sep;138(3 Suppl):107S-16S.
23. Forner LE, Dieleman FJ, Shaw RJ, et al. (2021). Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1. *Radiotherapy and Oncology*, 166, 137-144. Doi: <https://doi.org/10.1016/j.radonc.2021.11.021>
24. García-O'Farrill, N., Pugazhendhi, S., Karth, P. A., & Hunter, A. A. (2022, May). Radiation retinopathy intricacies and advances in management. In *Seminars in Ophthalmology* (Vol. 37, No. 4, pp. 417-435). Taylor & Francis.
25. Hadanny, A., et al., Reversibility of retinal ischemia due to central retinal artery occlusion by hyperbaric oxygen. *Clinical Ophthalmology* (Auckland, N.Z.), 2017. 11: p. 115-125.
26. Harch, P. G. (2022). Systematic review and dosage analysis: hyperbaric oxygen therapy efficacy in mild traumatic brain injury persistent postconcussion syndrome. *Frontiers in neurology*, 160. Retrieved from: <https://www.frontiersin.org/articles/10.3389/fneur.2022.815056/full>
27. Harch, P. G., Andrews, S. R., Rowe, C. J., Lischka, J. R., Townsend, M. H., Yu, Q., & Mercante, D. E. (2020). Hyperbaric oxygen therapy for mild traumatic brain injury persistent postconcussion

syndrome: a randomized controlled trial. *Medical gas research*, 10(1), 8. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871939/>

28. Hayes, Inc. Health Technology Assessment. *Topical Oxygen Therapy For Chronic Wound Healing*. Lansdale, PA: Hayes, Inc.; Nov 21, 2017. Last annual review Jan 18, 2021.
29. Hayes, Inc. Health Technology Assessment. *Systemic Hyperbaric Oxygen Therapy for Post-concussive Syndrome in Adults*. Lansdale, PA: Hayes, Inc.; Sept 14, 2022.
30. Health Quality Ontario. (2017). Hyperbaric oxygen therapy for the treatment of diabetic foot ulcers: a health technology assessment. *Ontario health technology assessment series*, 17(5), 1.
31. Hosokawa, S., et al., Prognostic factors for idiopathic sudden sensorineural hearing loss treated with hyperbaric oxygen therapy and intravenous steroids. *The Journal of Laryngology & Otology*, 2017. 131(1): p. 77-82.
32. Hu Q, Manaenko A, Xu T, Guo Z, Tang J, Zhang JH. Hyperbaric oxygen therapy for traumatic brain injury: bench-to-bedside. *Med Gas Res*. 2016 Jul 11;6(2):102-110. doi: 10.4103/2045-9912.184720. PMID: 27867476; PMCID: PMC5110132.
33. Huang, E., et al., A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers. *Undersea Hyperb Med*, 2015. 42(3): p. 205-47.
34. Hyperbaric Oxygen (HBO₂) for COVID-19 Patients. UHMS Position Statement. *Undersea Hyperb Med*. April 8, 2020.
35. Jirangkul, P., Baisopon, S., Pandaeng, D., & Srisawat, P. (2021). Hyperbaric oxygen adjuvant therapy in severe mangled extremities. *Injury*, 52(11), 3511-3515.
36. Johnson-Arbor, K., & Cooper, J. S. (2017). Hyperbaric Therapy In Blood Loss Anemia.
37. Jones, M. W., & Cooper, J. S. (2023, June 12). *Hyperbaric therapy for wound healing*. StatPearls - NCBI Bookshelf. <https://www.ncbi.nlm.nih.gov/books/NBK459172/>
38. Joshua TG, Ayub A, Wijesinghe P, Nunez DA. Hyperbaric Oxygen Therapy for Patients With Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. *JAMA Otolaryngol Head Neck Surg*. 2022;148(1):5–11. doi:10.1001/jamaoto.2021.2685
39. Kahng, P. W., Derakhshan, A., & Gadkaree, S. K. (2025). Hyperbaric oxygen therapy for wounds of the face, head and neck. *Current Opinion in Otolaryngology & Head and Neck Surgery*, 33(4), 222–229. <https://doi.org/10.1097/MOO.0000000000001053>
40. Kirby, J. P., Snyder, J., Schuerer, D. J. E., Peters, J. S., & Bochicchio, G. V. (2019). Essentials of Hyperbaric Oxygen Therapy: 2019 Review. *Missouri medicine*, 116(3), 176–179
41. Kranke, P., et al., Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database of Systematic Reviews*, 2015(6).
42. Kutz C.J., Kirby I.J., Grover I.R., et al. (2023). Aviation Decompression Sickness in Aerospace and Hyperbaric Medicine. *Aerospace Medicine and Human Performance*, 94(1), 11-17.
43. Lalieu, R. C., Akkerman, I., & van Hulst, R. A. (2021). Hyperbaric Oxygen Therapy for Venous Leg Ulcers: A 6 Year Retrospective Study of Results of a Single Center. *Frontiers in medicine*, 8, 671678. <https://doi.org/10.3389/fmed.2021.671678>
44. Mathieu, D., Marroni, A., & Kot, J. (2017). Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. *Diving and hyperbaric medicine*, 47(1), 24.

45. Martin, R., et al., Using hyperbaric oxygen for autism treatment: A review and discussion of the literature. *Undersea Hyperb Med*, 2015. 42(4): p. 353-9.
46. Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. *Diving Hyperb Med*. 2017 Mar;47(1):24-32.
47. Medicare Coverage Database Local Coverage Determination documents. [Internet] Centers for Medicare and Medicaid Services. Accessed at:
<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37873&ver=14&>.
48. Memar, M. Y., Yekani, M., Alizadeh, N., & Baghi, H. B. (2019). Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections. *Biomedicine & Pharmacotherapy*, 109, 440-447.
49. Mladenov, A., Diehl, K., Müller, O., von Heymann, C., Kopp, S., & Peitsch, W. K. (2022). Outcome of necrotizing fasciitis and Fournier's gangrene with and without hyperbaric oxygen therapy: a retrospective analysis over 10 years. *World Journal of Emergency Surgery*, 17(1), 43.
50. Moon, R. E., & Mitchell, S. J. (2021). Hyperbaric oxygen for decompression sickness. *Undersea & hyperbaric medicine: journal of the Undersea and Hyperbaric Medical Society, Inc*, 48(2), 195-203.
51. Oley MH, Oley MC, Noersasongko AD, et al. (2021) Effects of hyperbaric oxygen therapy on vascular endothelial growth factor protein and mRNA in crush injury patients: A randomized controlled trial study. *International Journal of Surgery Open*, 29, 33-39. Doi:
<https://doi.org/10.1016/j.ijso.2021.01.003>
52. Ortega, M. A., Fraile-Martinez, O., García-Montero, C., Callejón-Peláez, E., Sáez, M. A., Álvarez-Mon, M. A., ... & Canals, M. L. (2021). A general overview on the hyperbaric oxygen therapy: applications, mechanisms and translational opportunities. *Medicina*, 57(9), 864.
53. Pereira D., Ferreira C., Catarino R, et al. Hyperbaric oxygen for radiation-induced cystitis: A long-term follow-up, *Actas Urológicas Españolas (English Edition)*, Volume 44, Issue 8, 2020, Pages 561-567, ISSN 2173-5786, doi: <https://doi.org/10.1016/j.acuroe.2020.03.004>.
54. Sayadi, L.R., Banyard, D.A., & Ziegler, M.E., et al. (Jan 2018). Topical oxygen therapy & micro/nanobubbles: a new modality for tissue oxygen delivery. *International Wound Journal*, 15 (3), 363-374. Doi: <https://doi.org/10.1111/iwj.12873>
55. Sen S, Sen S. Therapeutic effects of hyperbaric oxygen: integrated review. *Med Gas Res*. 2021 Jan-Mar;11(1):30-33. doi: 10.4103/2045-9912.310057. PMID: 33642335; PMCID: PMC8103971.
56. Sharma, R., Sharma, S. K., Mudgal, S. K., Jelly, P., & Thakur, K. (2021). Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials. *scientific reports*, 11(1), 1-12
57. Sultan A, et al. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. *The Oncologist* 2017;22:343–350.
<http://doi.org/10.1634/theoncologist.2016-0298>

58. Sun, X. K., Li, R., Yang, X. L., & Yuan, L. (2022). Efficacy and safety of topical oxygen therapy for diabetic foot ulcers: An updated systematic review and meta-analysis. *International Wound Journal*, 19 (8), 2200-2209. Doi: <https://doi.org/10.1111/iwj.13830>
59. Toppen, W., Cho, N. Y., Sareh, S., Kjellberg, A., Medak, A., Benharash, P., & Lindholm, P. (2024). Contemporary national outcomes of hyperbaric oxygen therapy in necrotizing soft tissue infections. *PLOS One*, 19(3), e0300738. <https://doi.org/10.1371/journal.pone.0300738>
60. Undersea & Hyperbaric Medical Society (UHMS). 06b. Arterial inefficiencies: Enhancement of healing in selected problem wounds. In: Moon RE, ed. *UHMS Hyperbaric Oxygen Therapy Indications*. 14th ed. North Palm Beach, FL: Best Publishing Company; 2019. ISBN: 9781947239166.
61. Undersea and Hyperbaric Medical Society (UHMS). (2023). *Hyperbaric medicine indications manual* (E. T. Huang, Ed.; 15th ed.). Best Publishing Company.
<https://uhms.org/resources/featured-resources/hbo-indications.html>
62. Undersea & Hyperbaric Medical Society (UHMS). UHMS position statement: Topical oxygen for chronic wounds. 2018. Available at:
<https://www.uhms.org/uhm-search/uhm-journal-vol-45/number-3/uhms-position-statement-topical-oxygen-for-chronic-wounds.html>
63. U.S. Food & Drug Administration. Hyperbaric Oxygen Therapy: Get the Facts. Last updated July 26, 2021. Retrieved from:
https://www.fda.gov/consumers/consumer-updates/hyperbaric-oxygen-therapy-get-facts?utm_medium=email&utm_source=govdelivery
64. Vann, R.D., et al., Decompression illness. *The Lancet*. 377(9760): p. 153-164.
65. Villeirs L, Tailly T, Ost P, et al. Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy: Systematic review of the recent literature. *International Journal of Urology*, 27(2), 98-107.
66. Xiong, T., et al., Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD). *Cochrane Database of Systematic Reviews*, 2016(10)
67. Yip LT, Au SCL, Ko CKL. Hyperbaric oxygen therapy for central retinal artery occlusion: experience in Hong Kong. *Hong Kong J Ophthalmol* [Internet]. 2020 Dec.22 [cited 2023May9];24(2). Available from: <https://www.hkjo.hk/index.php/hkjo/article/view/281>
68. Yu J, Lu S, McLaren AM, Perry JA, Cross KM. Topical oxygen therapy results in complete wound healing in diabetic foot ulcers. *Wound Repair Regen*. 2016 Nov;24(6):1066-1072.

Clinical Guideline Revision / History Information

Original Date: 8/7/2017

Reviewed/Revised: 1/18/2018, 7/31/2018, 7/23/2019, 7/21/2020, 8/4/2021, 12/01/2021, 07/26/2022, 07/19/2023, 07/29/2024, 11/01/2025, 11/02/2026